Swiss-American biotechnology company, CRISPR Therapeutics AG (NASDAQ:CRSP) , has come under renewed pressure in recent weeks, amid insider sales, slow revenue growth, and weak adoption of its core products.The company, which often features at the top of several funds managed by Cathie Wood’s Ark Invest, such as the Ark Innovation ETF (BATS:ARKK) and the Ark Genomic Revolution ETF (BATS:ARKG) , is seeing its Momentum score slide over the past couple of days.Biotech Stock Sees Momentum SlideThe Momentum score ...